Literature DB >> 21875941

Reduced level of ribonucleotide reductase R2 subunits increases dependence on homologous recombination repair of cisplatin-induced DNA damage.

Z Ping Lin1, Yashang Lee, Fang Lin, Michael F Belcourt, Peining Li, Joseph G Cory, Peter M Glazer, Alan C Sartorelli.   

Abstract

Ribonucleotide reductase (RNR) catalyzes the rate-limiting step in the production of deoxyribonucleoside triphosphates (dNTPs) required for replicative and repair DNA synthesis. Mammalian RNR is a heteromeric enzyme consisting primarily of R1 and R2 subunits during the S phase of the cell cycle. We have shown previously that the presence of excess R2 subunits protects p53-deficient human colon cancer cells from cisplatin-induced DNA damage and replication stress. However, the mode of DNA repair influenced by changes in the level of the R2 subunit remained to be defined. In the present study, we demonstrated that depletion of BRCA1, an important factor of homologous recombination repair (HRR), preferentially sensitized stable R2-knockdown p53(-/-) HCT116 cells to the cytotoxicity of cisplatin and γ-H2AX induction. In accord with this finding, these R2-knockdown cells exhibited increased dependence on HRR, as evidenced by elevated levels of cisplatin-induced Rad51 foci and sister chromatid exchange frequency. Furthermore, stable knockdown of the R2 subunit also led to decreased cisplatin-induced gap-filling synthesis in nucleotide excision repair (NER) and a reduced dATP level in the G(2)/M phase of the cell cycle. These results suggest that an increased level of the R2 subunit extends the availability of dATP in the G(2)/M phase to promote the repair of NER-mediated single-strand gaps that are otherwise converted into double-strand breaks in the subsequent S phase. We propose that HRR becomes important for recovery from cisplatin-DNA lesions when the postexcision process of NER is restrained by reduced levels of the R2 subunit and dATP in p53-deficient cancer cells.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21875941      PMCID: PMC3228527          DOI: 10.1124/mol.111.074708

Source DB:  PubMed          Journal:  Mol Pharmacol        ISSN: 0026-895X            Impact factor:   4.436


  49 in total

1.  Surfing the p53 network.

Authors:  B Vogelstein; D Lane; A J Levine
Journal:  Nature       Date:  2000-11-16       Impact factor: 49.962

2.  Single-strand interruptions in replicating chromosomes cause double-strand breaks.

Authors:  A Kuzminov
Journal:  Proc Natl Acad Sci U S A       Date:  2001-07-17       Impact factor: 11.205

Review 3.  Specialized DNA polymerases, cellular survival, and the genesis of mutations.

Authors:  Errol C Friedberg; Robert Wagner; Miroslav Radman
Journal:  Science       Date:  2002-05-31       Impact factor: 47.728

Review 4.  Regulation of the G2/M transition by p53.

Authors:  W R Taylor; G R Stark
Journal:  Oncogene       Date:  2001-04-05       Impact factor: 9.867

5.  DNA double-strand breaks associated with replication forks are predominantly repaired by homologous recombination involving an exchange mechanism in mammalian cells.

Authors:  C Arnaudeau; C Lundin; T Helleday
Journal:  J Mol Biol       Date:  2001-04-13       Impact factor: 5.469

6.  A ribonucleotide reductase gene involved in a p53-dependent cell-cycle checkpoint for DNA damage.

Authors:  H Tanaka; H Arakawa; T Yamaguchi; K Shiraishi; S Fukuda; K Matsui; Y Takei; Y Nakamura
Journal:  Nature       Date:  2000-03-02       Impact factor: 49.962

7.  Multiple pathways of recombination define cellular responses to cisplatin.

Authors:  Z Z Zdraveski; J A Mello; M G Marinus; J M Essigmann
Journal:  Chem Biol       Date:  2000-01

8.  Chk1 is an essential kinase that is regulated by Atr and required for the G(2)/M DNA damage checkpoint.

Authors:  Q Liu; S Guntuku; X S Cui; S Matsuoka; D Cortez; K Tamai; G Luo; S Carattini-Rivera; F DeMayo; A Bradley; L A Donehower; S J Elledge
Journal:  Genes Dev       Date:  2000-06-15       Impact factor: 11.361

9.  The breast cancer susceptibility gene BRCA1 is required for subnuclear assembly of Rad51 and survival following treatment with the DNA cross-linking agent cisplatin.

Authors:  A Bhattacharyya; U S Ear; B H Koller; R R Weichselbaum; D K Bishop
Journal:  J Biol Chem       Date:  2000-08-04       Impact factor: 5.157

Review 10.  DNA interstrand crosslink repair in mammalian cells: step by step.

Authors:  Parameswary A Muniandy; Jia Liu; Alokes Majumdar; Su-ting Liu; Michael M Seidman
Journal:  Crit Rev Biochem Mol Biol       Date:  2010-02       Impact factor: 8.250

View more
  14 in total

Review 1.  Poly (ADP-ribose) polymerase inhibitors: on the horizon of tailored and personalized therapies for epithelial ovarian cancer.

Authors:  Elena S Ratner; Alan C Sartorelli; Z Ping Lin
Journal:  Curr Opin Oncol       Date:  2012-09       Impact factor: 3.645

2.  The Novel Ribonucleotide Reductase Inhibitor COH29 Inhibits DNA Repair In Vitro.

Authors:  Mei-Chuan Chen; Bingsen Zhou; Keqiang Zhang; Yate-Ching Yuan; Frank Un; Shuya Hu; Chih-Ming Chou; Chun-Han Chen; Jun Wu; Yan Wang; Xiyong Liu; D Lynne Smith; Hongzhi Li; Zheng Liu; Charles D Warden; Leila Su; Linda H Malkas; Young Min Chung; Mickey C-T Hu; Yun Yen
Journal:  Mol Pharmacol       Date:  2015-03-26       Impact factor: 4.436

3.  Triapine disrupts CtIP-mediated homologous recombination repair and sensitizes ovarian cancer cells to PARP and topoisomerase inhibitors.

Authors:  Z Ping Lin; Elena S Ratner; Margaret E Whicker; Yashang Lee; Alan C Sartorelli
Journal:  Mol Cancer Res       Date:  2014-01-10       Impact factor: 5.852

4.  Distinct mechanisms of cell-kill by triapine and its terminally dimethylated derivative Dp44mT due to a loss or gain of activity of their copper(II) complexes.

Authors:  Kimiko Ishiguro; Z Ping Lin; Philip G Penketh; Krishnamurthy Shyam; Rui Zhu; Raymond P Baumann; Yong-Lian Zhu; Alan C Sartorelli; Thomas J Rutherford; Elena S Ratner
Journal:  Biochem Pharmacol       Date:  2014-08-15       Impact factor: 5.858

5.  Novel immunosuppressive agent caerulomycin A exerts its effect by depleting cellular iron content.

Authors:  Suneet Kaur; Gautam Srivastava; Amar Nath Sharma; Ravinder S Jolly
Journal:  Br J Pharmacol       Date:  2015-02-10       Impact factor: 8.739

6.  Knockdown of NFBD1/MDC1 enhances chemosensitivity to cisplatin or 5-fluorouracil in nasopharyngeal carcinoma CNE1 cells.

Authors:  Quan Zeng; Zhihai Wang; Chuan Liu; Zhitao Gong; Li Yang; Liang Jiang; Zuxia Ma; Yi Qian; Yucheng Yang; Houyong Kang; Suling Hong; Youquan Bu; Guohua Hu
Journal:  Mol Cell Biochem       Date:  2016-06-23       Impact factor: 3.396

7.  The expression of ribonucleotide reductase M2 in the carcinogenesis of uterine cervix and its relationship with clinicopathological characteristics and prognosis of cancer patients.

Authors:  Ying-Fang Su; Tzu-Fan Wu; Jiunn-Liang Ko; Hsiu-Ting Tsai; Yi-Torng Tee; Ming-Hsien Chien; Chi-Hung Chou; Wea-Lung Lin; Hui-Ying Low; Ming-Yung Chou; Shun-Fa Yang; Po-Hui Wang
Journal:  PLoS One       Date:  2014-03-17       Impact factor: 3.240

Review 8.  Regulation of mammalian nucleotide metabolism and biosynthesis.

Authors:  Andrew N Lane; Teresa W-M Fan
Journal:  Nucleic Acids Res       Date:  2015-01-27       Impact factor: 16.971

9.  Prolonged pemetrexed pretreatment augments persistence of cisplatin-induced DNA damage and eliminates resistant lung cancer stem-like cells associated with EMT.

Authors:  Colin Charles Tièche; Ren-Wang Peng; Patrick Dorn; Laurène Froment; Ralph Alexander Schmid; Thomas Michael Marti
Journal:  BMC Cancer       Date:  2016-02-19       Impact factor: 4.430

10.  Triapine potentiates platinum-based combination therapy by disruption of homologous recombination repair.

Authors:  Elena S Ratner; Yong-Lian Zhu; Philip G Penketh; Julie Berenblum; Margaret E Whicker; Pamela H Huang; Yashang Lee; Kimiko Ishiguro; Rui Zhu; Alan C Sartorelli; Z Ping Lin
Journal:  Br J Cancer       Date:  2016-03-10       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.